期刊文献+

基质金属蛋白酶-9和表皮生长因子受体在非小细胞肺癌中的表达及相关性研究

Study on expression and relationship between MMP-9 and EGFR in NSCLC
下载PDF
导出
摘要 目的 :探讨基质金属蛋白酶 9(MMP 9)和表皮生长因子受体 (EGFR)在非小细胞肺癌 (NSCLC)中的表达关系和预后意义。 方法 :采用免疫组化 (S P)法检测MMP 9和EGFR在 6 2例NSCLC组织和 18例正常肺组织中的表达。 结果 :6 2例NSCLC中MMP 9和EGFR阳性表达率分别为 6 7.7%和 5 8.1% ,显著高于 18例癌旁正常肺组织 (P <0 .0 0 5 )。MMP 9和EGFR的表达与肿瘤TNM分期、分化程度及淋巴结转移有关 (P <0 .0 5 )。MMP 9和EGFR的表达呈正相关 (χ2 =6 .4 5 ,P <0 .0 5 )。MMP 9和EGFR与患者的预后密切相关 (P <0 .0 5 )。 结论 :MMP 9。 Objective:To evaluate the relationship and prognostic significance of matrix metalloproteinase-9(MMP-9)、epidermal growth factor receptor(EGFR) in patients with non- small cell lung cancer(NSCLC). Methods:Immunohistochemical method (S-P) was used to detect the expression of the MMP-9、EGFR in 62 NSCLC tissues and 18 normal lung tissues. Results:The positive expression rates of MMP-9 and EGFR were 67.7%,58.1% respectively in the 62 NSCLC.Their expression levels were significantly higher than those in 18 para-cancerous normal lung tissues(P< 0.005).The positive rate of MMP-9、EGFR in lung cancer were closely related to the TNM stages, pathological grades and lymph node involvement(P<0.05).There was the correlation between the MMP-9 and EGFR(χ 2=6.45,P< 0.05).The levels of MMP-9 and EGFR expression were associated with unfavovable prognosis. Conclusion:MMP-9,EGFR could be used as markers of malignant potential and prognosis factor of NSCLC.
作者 徐晓辉 王耿
出处 《医学研究生学报》 CAS 2004年第10期901-903,907,F002,共5页 Journal of Medical Postgraduates
关键词 基质金属蛋白酶9 表皮生长 因子受体 非小细胞肺癌 Matrix metalloproteinase-9 Epidermal growth factor Receptor Non small cell lung cancer
  • 相关文献

参考文献1

二级参考文献19

  • 1David E, Kleine R, William G, et al. Matrix metallproteinases and metastasis[J]. Cancer Chemother Pharmacol,1999,43:42-51.
  • 2Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease[J]. Biological Chemistry Hoppe Seyler, 1995, 376(6):345- 355.
  • 3Sang QX, Birkeda-hansen H, Vanwart HE. Proteolytic and non-proteolytic activation of human neutrophil progelatinase B[J]. Biochim Biophys Acta, 1995, 1251(2): 99-108.
  • 4Stetler-stevenson WG. Matrix metalloproteinase inhibitors, in cancer therapeutics: experimental and clinical agents (ed: Teicher, B) [M].Totowa, NJ: Humana Press Inc. 1997,241- 262.
  • 5Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4[J].J Biol Chem,1996,271 (48) :30375 - 30380.
  • 6Ieng ZS, Guille M. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases[J]. Br J Cancer, 1995,72:575- 579.
  • 7Kleiner D, Stetler-stevenson W. Cancer Chemother Pharmacol, 1999,43(suppl): 42-51.
  • 8Farias E, Ranuncolo S, Cresta C, et al. Plasma metal oproteinase ectivity is enhanced in the ecglobulin fraction of breast and lung cancer patients[J]. Int J Cancer, 2000,89(4):389-394.
  • 9Thomas P, Khokha R, Shepherd FA, et al. Differential expression of MMPs and their inhibitors in non-small cell lung cancer[J]. J Pathol,2000,190(2): 150 - 156.
  • 10Suzuki M, IizasaT, FujisawaT, etal. Expression of matrix metalloproteinases and tissue inhibitor of natrix metalloproteinases in non-small-cell lung cancer[J]. Invasion Metastasis, 98-99, 18 (3):134- 141.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部